BenchSci Revenue and Competitors

Toronto, ON CAN

Location

$997M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • BenchSci's estimated annual revenue is currently $101.6M per year.(i)
  • BenchSci received $50.0M in venture funding in January 2022.
  • BenchSci's estimated revenue per employee is $217,000
  • BenchSci's total funding is $997M.

Employee Data

  • BenchSci has 468 Employees.(i)
  • BenchSci grew their employee count by -11% last year.

BenchSci's People

NameTitleEmail/Phone
1
Founder and CSOReveal Email/Phone
2
Co-founder and CEOReveal Email/Phone
3
Chief Solution ArchitectReveal Email/Phone
4
Chief Staff, PlatformReveal Email/Phone
5
Chief Staff to the CEOReveal Email/Phone
6
Chief StaffReveal Email/Phone
7
VP, Portfolio Performance SolutionsReveal Email/Phone
8
VP Commercial OperationsReveal Email/Phone
9
EVPReveal Email/Phone
10
VP MarketingReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.7M9-72%$39.4MN/A
#2
$0.9M11-83%$23.8MN/A
#3
$87.6M5656%N/AN/A
#4
$2.8M1813%N/AN/A
#5
$7.8M50-68%N/AN/A
#6
$13.5M8730%N/AN/A
#7
$17.8M115-6%N/AN/A
#8
$0.9M11-39%N/AN/A
#9
$13.6M88-20%$86MN/A
#10
$20M129-12%N/AN/A
Add Company

What Is BenchSci?

BenchSci’s vision is to bring novel medicine to patients 50% faster by 2025. We’re achieving it by empowering scientists with the world’s most advanced biomedical artificial intelligence. For biomedical researchers and academics who are starting experiments, BenchSci offers a reagent intelligence platform that transforms published data into experiment-specific recommendations to reduce time, money and uncertainty in planning materials and methods. Unlike PubMed, Google Scholar, reagent directories, and vendors, BenchSci uses machine learning to decode open- and closed-access data, pre-print data, and data from third-party databases to present published figures with actionable insights. Backed by top-tier investors including Inovia Capital, TCV, F-Prime, Gradient Ventures (Google’s AI fund), and Golden Ventures, BenchSci's platform accelerates science at 16 top-20 pharmaceutical companies and over 4,500 leading research centers worldwide. We’re a remote-first Deloitte Tech Fast 50 and CIX Top 10 Growth company, certified Great Place to Work®, and top-ranked company on Glassdoor. Learn more at www.benchsci.com.

keywords:Biotechnology, Life Sciences, Pharmaceuticals, Machine Learning, Artificial Intelligence, Deep Learning, Science

$997M

Total Funding

468

Number of Employees

$101.6M

Revenue (est)

-11%

Employee Growth %

N/A

Valuation

N/A

Accelerator

BenchSci News

2022-04-20 - Former Shopify CTO Jean-Michel Lemieux joins BenchSci advisory ...

Ex-Shopify CTO Jean-Michel Lemieux has joined the advisory board of BenchSci, a pharmaceutical research support company focused on cutting...

2020-02-04 - BenchSci raises $29 million CAD Series B round

BenchSci has raised a $29 million CAD ($22 million USD) Series B funding round led by F-Prime Capital. The financing round also saw participation from Venture Capital Catalyst Initiative (VCCI) – backed Northleaf Capital Partners and return investors including Google’s AI venture fund Gradient ...

2020-02-04 - BenchSci Raises $22M in Series B Funding

BenchSci, a Toronto, Canada-based provider of a machine learning platform to identify and resolve preclinical research inefficiencies in drug discovery, raised $22m in Series B financing. The round was led by F-Prime Capital, with participation from Northleaf Capital Partners and existing inves ...

2019-08-29 - Software Ate The World, Now AI Is Eating Software

... aiming to automate the very costly process of drug development in the pharmaceutical industry according to a recent update on BenchSci.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$76.1M468-17%N/A
#2
$148.9M4699%N/A
#3
$158.6M470-1%N/A
#4
$134.2M4732%N/A
#5
$60.4M47410%N/A

BenchSci Funding

DateAmountRoundLead InvestorsReference
2018-05-03$10.0MAInovia CapitalArticle
2020-02-04$22.0MBF-Prime CapitalArticle
2022-01-24$50.0MCInovia Capital, TCVArticle